Clinical TrialsClinical Trials in California
Reviewed by Michael Gill, B. Sc.
Image of University of California Los Angeles Medical Center in Los Angeles, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

PRO1184for erbB-2 Receptor

18+
All Sexes
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A of the study will find out how much and how frequently PRO1184 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1184 is and if it works to treat solid tumor cancers.
Phase 1 & 2
Recruiting
University of California Los Angeles Medical Center (+9 Sites)ProfoundBio US Co.
Image of USPA Advance Concept Medical Research Group LLC in Miami, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Nirmatrelvir Plus Ritonavir For 5 Daysfor COVID19 (disease)

Any Age
All Sexes
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: Have completed treatment with nirmatrelvir/ritonavir Have a rebound in COVID-19 symptoms Are SARS-CoV-2 (COVID-19) positive All study medications will be taken 2 times a day by mouth for 5 days. The first dose of study medication is taken at the study clinic and the rest at home. We will examine the experiences of people receiving the study medicines to those who do not. This will help us determine if the study medicines are safe and effective. People taking part will be in this study for about 24 weeks. Enrolled participants will need to visit the study clinic at least 8 times during the study.
Phase 2
Recruiting
USPA Advance Concept Medical Research Group LLC (+10 Sites)Pfizer CT.gov Call CenterPfizer
Image of Research Site in Nashville, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Cohort Bfor Breast Cancer

18+
All Sexes
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems. Olaparib is a type of drug called a PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Durvalumab is a type of anticancer drug called immunotherapy that targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. Your immune system can then attack and kill the cancer cells. Durvalumab is approved by the FDA and the EMA for the treatment of patients with locally advanced non-small cell lung cancer after receiving chemoradiation therapy and extensive-stage small cell lung cancer in combination with chemotherapy. Some parts of this study are experimental, which means that durvalumab and the combination of olaparib and durvalumab are still in the development stage for the treatment of breast cancer, and they are not approved for treatment of breast cancer, except for use in research studies like this.
Phase 2
Recruiting
Research Site (+9 Sites)Anitra Fielding, MBChBAstraZeneca
Image of DaVita Inglewood Dialysis in Inglewood, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

PF-07321332 (nirmatrelvir)/ritonavir Participants With Severe Renal Impairment On Hemodialysisfor COVID19 (disease)

18+
All Sexes
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment. The study will also look at the amounts of study drug in your blood. There will be 24 participants in this study; 12 of them will have severe renal impairment and not be on hemodialysis and 12 of them will be on hemodialysis. All participants in this study will take PF-07321332 (nirmatrelvir)/ritonavir by mouth for 5 days. During this time, they will have to collect blood samples to measure the study drug levels in their blood. After taking the study drug for 5 days, the participants will have follow-up visits for about another 28 days for a total of about 34 days in the study. The study team will check how each participant is doing during regular visits at the study clinic.
Phase 1
Recruiting
DaVita Inglewood Dialysis (+36 Sites)Pfizer CT.gov Call CenterPfizer
25 California Clinical Trials Near Me
Top Cities for California Clinical Trials
Image of Los Angeles in California.
Los Angeles
215Active Trials
Kaiser Permanente Los Angeles Medical CenterTop Active Site
Image of Miami in Florida.
Miami
140Active Trials
University of Miami Miller School of Medicine-Sylvester Cancer CenterTop Active Site